Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THINK
NCT05732727Phase 3Recruiting
- Sponsor
- University Hospital Tours
- Start
- Mar 2023
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hypertension (HTN) (2 arms), sponsored by University Hospital Tours. Primary endpoints: End stage kidney disease up to 36 months, eGFR decline of at least 40% up to 36 months and 2 more. Started Mar 2023; status: recruiting.
02
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05732727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05732727.